



See you
next year!

medtech-showcase.com



MEDTECH SHOWCASE

JANUARY 12, 2016 // SAN FRANCISCO, CA USA

INVESTOR SUMMARY PROFILES OF PRESENTING COMPANIES



360

Follow this event:
Search by: #MTS16

Co-produced by

EBD
GROUP

DEMY
COLTON

THANK YOU SPONSORS!

SILVER SPONSOR



A Symbol of Excellence

SUPPORTING ORGANIZATIONS



AdvaMed

Advanced Medical Technology Association



MEDEC

CANADA'S MEDICAL DEVICE TECHNOLOGY COMPANIES
LES SOCIÉTÉS CANADIENNES DE TECHNOLOGIE DES
DISPOSITIFS MÉDICAUX

Minnesota

Department of Employment and Economic Development



SEMDA

Medical devices. **For life.**

**8–9:15am MEDTECH SHOWCASE
STATE OF THE INDUSTRY REPORT**

The rise of personalized, or precision, medicine is creating a convergence of traditional therapeutic biopharmaceutical products with innovative diagnostic and/or drug delivery technologies.

In recognition of this convergence, executives with deep experience in the device and diagnostic industry will discuss the latest technologies with an eye to how they will help advance biopharmaceutical innovation. By addressing regulatory issues related to combination products, the cultural challenges of working across the medical technology and biopharm sectors, financing and intellectual property considerations, this plenary will help provide an understanding of the opportunities, as well as the risks, that these new technologies bring.

MODERATOR: Vicki Anastasi – VP and Global Head, Medical Device and Diagnostics Research, ICON

SPEAKERS:

- **Patrick Daly** – Board Member, AdvaMed;
President and CEO, Cohera Medical
- **Andrew Fish** – Executive Director, AdvaMedDx;
Senior Executive VP, AdvaMed
- **Bill Murray** – President and CEO, Medical Device Innovation Consortium (MDIC)

9:30am–12:30pm COMPANY PRESENTATIONS

12:30–1:30pm LUNCHEON
Level 4, Cyril Magnin Foyer

1:30–4:30pm COMPANY PRESENTATIONS

TUESDAY

JANUARY 12, 2016

Level 3, Market Street

AGENDA

4:30–5:30pm

MEDTECH SHOWCASE WORKSHOP

Advanced medical technology: What investors need to know

By reducing adverse side effects, increasing compliance and identifying the right therapy for each patient, advanced drug delivery and diagnostics are key tools in our quest to improve the precision of advanced therapeutics. This session will highlight the investment opportunities in this exciting sector and identify the key factors investors and partners are looking for in companies.

MODERATOR: Christian Haller – President, RavenOye Group

SPEAKERS:

- **Stephen Dunn** – Senior Managing Director of Research, LifeTech Capital
- **Vijay Pande** – General Partner, Andreessen Horowitz
- **Phyllis E. Whiteley** – Venture Partner, Mohr Davidow Ventures
- **Peter Young** – Executive-in-Residence, Pappas Capital

Acarix A/S

The Acarix CADScor® System was developed to rule out suspected coronary artery disease (CAD) based on the detection of functionally related heart sounds originating from reduced myocardial blood flow. CADScor® System provides a safe, cost-effective and easy non-invasive evaluation of patients with suspected CAD.

Location: Lyngby, Denmark

Year Established: 2009 *Website:* www.acarix.com

Therapeutic Focus: Non invasive cardiovascular diagnostic devices

Technology/Target: The Acarix CADScor® System is developed to non-invasively rule out suspected coronary artery disease (CAD) in symptomatic patients

Development Status: Pre launch. Commercial from mid 2016

Corporate Partners: NA

Funds Raised: €11M to date, of which approx. €1.5M are non dilutive grants

Presenter: Stig Andersen, CEO

Amedica Corporation (NASDAQ: AMDA)

Amedica Corporation is a commercial stage biomaterial platform company focused on the development of silicon nitride ceramics. The Company's spine products are FDA-cleared, CE-marked, and are currently marketed in the U.S. and select markets in Europe and South America through its distributor network and its growing OEM partnerships.

Location: Salt Lake City, Utah United States

Year Established: NA *Website:* www.amedica.com

Therapeutic Focus: NA

Technology/Target: NA

Development Status: NA

Corporate Partners: NA

Funds Raised: NA

Presenter: Sonny Bal, Chairman, President & CEO

Vertical Spine, LLC

Vertical Spine is a commercial stage orthobiologics company with a unique, high yield, easy to use system providing intra-procedural collection and highly consistent preparation of two autologous Platelet-rich Fibrin Matrix (PRFM) Membrane Grafts and a Surgeon-Defined Graft in forms that facilitate targeted placement in the spine.

Location: Wall, New Jersey, United States

Year Established: 2010 *Website:* www.verticalspine.com

Therapeutic Focus: Advanced Spinal Biologics

Technology/Target: Autologous orthobiologic technology

Development Status: FIBRINET® products have been successfully used in over 900 cases at the Hospital for Special Surgery and Columbia Presbyterian, NYC

Corporate Partners: NA

Funds Raised: Approx. \$1M

Presenter: Tom Crowley, Chairman & CEO

PLEASE NOTE:

Please refer to the Conference Update Sheet distributed daily at the Registration Area for Summaries of Presenting Companies that missed the submission deadline for this publication.

The information contained in this book is current as of January 6, 2016 and was obtained through sources believed to be reliable, including information provided by the company representatives and company web sites. Information was edited to fit into the format of this book.

Demy-Colton Life Science Advisors and EBD Group, the organizers of Biotech Showcase™, Medtech Showcase and Digital Health Showcase do not guarantee that this information is complete or correct, nor do they warrant the information for a particular purpose. The organizers do not underwrite securities or make markets in them. The presenting companies may participate in other meetings produced by the organizers.